Predicting trajectories of lung function decline in systemic sclerosis-related interstitial lung disease
- PMID: 40457812
- PMCID: PMC12596066
- DOI: 10.1093/rheumatology/keaf270
Predicting trajectories of lung function decline in systemic sclerosis-related interstitial lung disease
Abstract
Objective: SSc-related interstitial lung disease (SSc-ILD) is a major cause of morbidity. We aimed to identify patients following similar trajectories of forced vital capacity (FVC) decline, and examine their association with mortality and risk factors for FVC decline.
Methods: This is a multicentre retrospective study of 444 SSc patients with ILD and ≤7-year disease duration. Patients were grouped based on similar FVC decline trajectories using semi-parametric modelling with latent class analysis. Survival was compared between the worst FVC trajectory group and the others. Logistic regression models with backwards selection were applied to identify predictors of FVC trajectory using baseline disease features.
Results: Four FVC trajectory groups were identified. The most progressive trajectory declined by -2.18% per year and the other three trajectory groups were stable or progressed slowly. The most progressive group had a higher mortality rate than those with a stable/slow FVC trajectory (hazard ratio 2.95, 95% CI 1.74, 4.98). Baseline FVC (P < 0.001) and CRP elevation (P = 0.039) were associated the progressive trajectory. Baseline FVC ≤72% predicted the progressive trajectory with a sensitivity of 0.88 and specificity of 0.91. A lower baseline FVC was in turn associated with older age, Caucasian race, longer disease duration, anti-topoisomerase I presence and elevated CRP on exploratory analyses.
Conclusion: Distinct FVC trajectories are associated with different survival outcomes and the most important predictor of a progressive FVC trajectory was existing ILD severity. More work is needed to assess the utility of imaging or paraclinical findings that can improve prediction of distinct FVC trajectories.
Keywords: forced vital capacity; interstitial lung disease; mortality; scleroderma; systemic sclerosis.
© The Author(s) 2025. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
References
-
- Nasser M, Larrieu S, Boussel L et al. Prevalence and mortality of systemic sclerosis-associated interstitial lung disease (SSc-ILD) using the French national health insurance system (SNDS) database in France. Eur Respir J 2020;56:805.
-
- Tashkin DP, Roth MD, Clements PJ et al. ; Sclerodema Lung Study II Investigators. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 2016;4:708–19. - PMC - PubMed
-
- Distler O, Highland KB, Gahlemann M et al. ; SENSCIS Trial Investigators. Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease. New England Journal of Medicine 2019;380:2518–28. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
